US-based interventional technologies provider NICO has secured a CE mark for its patented technology 'BrainPath' to provide non-disruptive access to the brain.
Designed to be compatible with a parafascicular and trans-sulcal surgical approach, the technology will now be available in more than 30 countries in the European Union (EU).
A part of new standardised brain surgery approach, BrainPath runs parallel to the fibre tracts as a path to the surgical site, utilising the natural folds of the brain.
The approach achieves non-disruptive access and automated tissue removal / clot evacuation, as well as intraoperative tumour tissue collection and preservation through a combination of patented technologies.
BrainPath unites imaging and intervention to provide guided atraumatic access within the brain via trans-sulcal, parafascicular surgical approach.
It gently moves the brain tissue to generate a corridor to the tumour or hemorrhage site.
NICO president and chief executive officer Jim Pearson said: “Gaining CE mark approval for BrainPath is our first step in answering increasing global interest in a systems approach to subcortical brain surgery using a standardised approach.
“We intend to take a planned approach to global expansion and look forward to making a positive difference in the worldwide brain tumour and stroke incidence rate.”
Intended for subcortical access, BrainPath can be used for specific indications such as primary and secondary brain tumours, vascular abnormalities resulting in intracerebral hemorrhage (ICH) or hemorrhagic stroke and secondary bleeds, and intraventricular tumours or cysts.
Based on the available clinical data, BrainPath is reported to show overall safety, performance and can be used anywhere in the white matter of the brain.
Image: NICO BrainPath patented technology. Photo: courtesy of Business Wire.
